The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Progressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory Therapies
Abstract
Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the white matter of the human brain caused by lytic infection of oligodendrocytes with the human polyomavirus JCV. Although the majority of PML cases occur in severely immune-suppressed individuals, with HIV-1 infection as the predominant factor, PML has been increasingly diagnosed in patients treated with biological therapies such as monoclonal antibodies that modulate immune system functions. Monoclonal antibodies that target the cell adhesion molecules VLA-4 (natalizumab; Tysabri® for multiple sclerosis and Crohn's disease) or LFA-1 (efalizumab; Raptiva® for severe forms of plaque psoriasis) to prevent extravasation of inflammatory T cells into tissues, or target the cell surface marker CD20 (rituximab; Rituxan® for hematologic malignancies and rheumatoid arthritis) to deplete peripheral circulating B cells, have all been associated with PML. The link between the effects of these therapies on the immune system and the occurrence of PML has prompted investigations on JCV sites of latency in the bone marrow, the migration of bone marrow derived cells into the circulation, and intracellular virus entry into the brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CULTIVATION OF PAPOVA-LIKE VIRUS FROM HUMAN BRAIN WITH PROGRESSIVE MULTIFOCAL LEUCOENCEPHALOPATHY
Padgett, B., Zurhein, G., Walker, D., Eckroade, R., & Dessel, B. (1971) · The Lancet · doi:10.1016/s0140-6736(71)91777-6 · Cited by 1,624
Kleinschmidt-DeMasters, B. K., & Tyler, K. L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051782 · Cited by 1,072
Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease
Van Assche, G., Van Ranst, M., Sciot, R., Dubois, B., Vermeire, S., Noman, M., Verbeeck, J., Geboes, K., Robberecht, W., & Rutgeerts, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051586 · Cited by 1,060
Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab
Langer-Gould, A., Atlas, S. W., Green, A. J., Bollen, A. W., & Pelletier, D. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051847 · Cited by 1,034
Carson, K. R., Evens, A. M., Richey, E. A., Habermann, T. M., Focosi, D., Seymour, J. F., Laubach, J., Bawn, S. D., Gordon, L. I., Winter, J. N., et al. (2009) · Blood · doi:10.1182/blood-2008-10-186999 · Cited by 866
Self-citationÅSTRÖM, K.-E., MANCALL, E. L., & RICHARDSON, E. P. (1958) · Brain · doi:10.1093/brain/81.1.93 · Cited by 832
Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy
Yousry, T. A., Major, E. O., Ryschkewitsch, C., Fahle, G., Fischer, S., Hou, J., Curfman, B., Miszkiel, K., Mueller-Lenke, N., Sanchez, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054693 · Cited by 790
Self-citationKnowles, W. A., Pipkin, P., Andrews, N., Vyse, A., Minor, P., Brown, D. W. G., & Miller, E. (2003) · Journal of Medical Virology · doi:10.1002/jmv.10450 · Cited by 586
The Human Polyomavirus, JCV, Uses Serotonin Receptors to Infect Cells
Elphick, G. F., Querbes, W., Jordan, J. A., Gee, G. V., Eash, S., Manley, K., Dugan, A., Stanifer, M., Bhatnagar, A., Kroeze, W. K., et al. (2004) · Science · doi:10.1126/science.1103492 · Cited by 475
Immune surveillance in multiple sclerosis patients treated with natalizumab
Stüve, O., Marra, C. M., Jerome, K. R., Cook, L., Cravens, P. D., Cepok, S., Frohman, E. M., Phillips, J. T., Arendt, G., Hemmer, B., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20858 · Cited by 434
Particles Resembling Papova Viruses in Human Cerebral Demyelinating Disease
Zu Rhein, G. M., & Chou, S.-M. (1965) · Science · doi:10.1126/science.148.3676.1477 · Cited by 421
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring
Kappos, L., Bates, D., Hartung, H.-P., Havrdova, E., Miller, D., Polman, C. H., Ravnborg, M., Hauser, S. L., Rudick, R. A., Weiner, H. L., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70078-9 · Cited by 421
Self-citationIntegrin-Mediated Long-Term B Cell Retention in the Splenic Marginal Zone
Lu, T. T., & Cyster, J. G. (2002) · Science · doi:10.1126/science.1071632 · Cited by 382
Houff, S. A., Major, E. O., Katz, D. A., Kufta, C. V., Sever, J. L., Pittaluga, S., Roberts, J. R., Gitt, J., Saini, N., & Lux, W. E. (1988) · New England Journal of Medicine · doi:10.1056/nejm198802043180507 · Cited by 327
Self-citationMonaco, M. C., Atwood, W. J., Gravell, M., Tornatore, C. S., & Major, E. O. (1996) · Journal of Virology · doi:10.1128/jvi.70.10.7004-7012.1996 · Cited by 293
Self-citationStüve, O., Marra, C. M., Bar-Or, A., Niino, M., Cravens, P. D., Cepok, S., Frohman, E. M., Phillips, J. T., Arendt, G., Jerome, K. R., et al. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1383 · Cited by 271
Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name?
Koralnik, I. J. (2006) · Annals of Neurology · doi:10.1002/ana.20933 · Cited by 243
White, F. A., Ishaq, M., Stoner, G. L., & Frisque, R. J. (1992) · Journal of Virology · doi:10.1128/jvi.66.10.5726-5734.1992 · Cited by 221
Progressive Multifocal Leukoencephalopathy after Natalizumab Monotherapy
Lindå, H., von Heijne, A., Major, E. O., Ryschkewitsch, C., Berg, J., Olsson, T., & Martin, C. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810316 · Cited by 218
Self-citationDu Pasquier, R. A. (2004) · Brain · doi:10.1093/brain/awh215 · Cited by 208
Zohren, F., Toutzaris, D., Klärner, V., Hartung, H., Kieseier, B. C., & Haas, R. R. (2008) · Blood · doi:10.1182/blood-2007-10-120329 · Cited by 193
Productive infection of cerebellar granule cell neurons by JC virus in an HIV+ individual
Pasquier, R. D., Corey, S., Margolin, D. H., Williams, K., Pfister, L., Girolami, U. D., Key, J. J. M., Wüthrich, C., Joseph, J. T., & Koralnik, I. J. (2003) · Neurology · doi:10.1212/01.wnl.0000081306.86961.33 · Cited by 154
Ransohoff, R. M. (2005) · Nature Neuroscience · doi:10.1038/nn1005-1275 · Cited by 141
Sunyaev, S. R., Lugovskoy, A. A., Simon, K. J., & Gorelik, L. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000368 · Cited by 139
Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons
Wüthrich, C., Dang, X., Westmoreland, S. V., McKay, J., Maheshwari, A., Anderson, M. P., Ropper, A. H., Viscidi, R. P., & Koralnik, I. J. (2009) · Annals of Neurology · doi:10.1002/ana.21619 · Cited by 138
Koralnik, I. J., Pasquier, R. D., Kuroda, M. J., Schmitz, J. E., Dang, X., Zheng, Y., Lifton, M. A., & Letvin, N. L. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.1.499 · Cited by 135
Detection of JC virus DNA fragments but not proteins in normal brain tissue
Pérez-Liz, G., Valle, L. D., Gentilella, A., Croul, S. E., & Khalili, K. (2008) · Annals of Neurology · doi:10.1002/ana.21443 · Cited by 130
Dubois, V., Dutronc, H., Lafon, M., Poinsot, V., Pellegrin, J., Ragnaud, J. M., Ferrer, A. M., & Fleury, H. J. (1997) · Journal of Clinical Microbiology · doi:10.1128/jcm.35.9.2288-2292.1997 · Cited by 115
Interaction of the human polyomavirus, JCV, with human B-lymphocytes
Atwood, W. J., Amemiya, K., Traub, R. G., Harms, J., & Major, E. O. (1992) · Virology · doi:10.1016/0042-6822(92)90909-9 · Cited by 111
Self-citationAj, A., Jl, S., & Major, E. O. (1986) · Neurology · doi:10.1212/wnl.36.4.499 · Cited by 83
Self-citationMulticenter Comparison of PCR Assays for Detection of Human Herpesvirus 6 DNA in Serum
Flamand, L., Gravel, A., Boutolleau, D., Álvarez‐Lafuente, R., Jacobson, S., Malnati, M., Kohn, D. J., Tang, Y., Yoshikawa, T., & Ablashi, D. V. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00370-08 · Cited by 79
Opportunistic infections and other risks with newer multiple sclerosis therapies
Berger, J. R., & Houff, S. A. (2009) · Annals of Neurology · doi:10.1002/ana.21630 · Cited by 62
Guttman‐Yassky, E., Vugmeyster, Y., Lowes, M. A., Chamian, F. N., Kikuchi, T., Kagen, M. H., Gilleaudeau, P., Lee, E., Hunte, B., Howell, K., et al. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.4 · Cited by 59
Cited by
Targeting integrin pathways: mechanisms and advances in therapy
Pang, X., He, X., Qiu, Z., Zhang, H., Xie, R., Liu, Z., Gu, Y., Zhao, N., Xiang, Q., & Cui, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01259-6 · Cited by 1,275
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
Bloomgren, G., Richman, S., Hotermans, C., Subramanyam, M., Goelz, S., Natarajan, A., Lee, S., Plavina, T., Scanlon, J. V., Sandrock, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1107829 · Cited by 1,242
The safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,144
Anti-inflammatory Agents: Present and Future
Dinarello, C. A. (2010) · Cell · doi:10.1016/j.cell.2010.02.043 · Cited by 1,095
Myelin in the Central Nervous System: Structure, Function, and Pathology
Stadelmann, C., Timmler, S., Barrantes-Freer, A., & Simons, M. (2019) · Physiological Reviews · doi:10.1152/physrev.00031.2018 · Cited by 728
Metadata
- Authors
- Major, E. O.
- Venue
- Annual Review of Medicine
- Publisher
- Annual Reviews
- Published
- 2010-02-01
- Volume
- 61
- Issue
- 1
- Pages
- 35-47
- ISSN
- 0066-4219 (ISSN-L)
- 1545-326X
- OpenAlex
- W2140463009
- Cited by
- 437
- References
- 33
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.